Mechanisms for Assembling and Resolving Naïve Pluripotency

Speakers
  • Assistant Professor, Weizmann Institute of Science
    Biography
      Dr. Hanna earned a B.Sc. in Medical Sciences (2001, summa cum laude), and a PhD/MD in clinical medicine (2007, summa cum laude), all from the Hebrew University of Jerusalem, Israel. For more than four years, he conducted postdoctoral research with Prof. Rudolf Jaenisch at the Whitehead Institute for Biomedical. In his recently established lab at the Weizmann Institute, Dr. Hanna combines diverse experimentation methods with computational biology to explore topics in embryonic stem cell biology, early embryonic development and the modeling of human diseases. Projects include deciphering the mechanisms by which IPS and germ cells are produced, characterizing unique naïve human pluripotent stem cells and various stages in early human development. In addition to helping elucidate the molecular basis of cell reprogramming, this research offers the promise of creating powerful research models for infertility, cancer, degenerative and autoimmune diseases such as type 1 diabetes.

      His numerous honors and fellowships include a Novartis Fellowship by the Helen Hay Whitney Foundation (2007), a Genzyme-Whitehead Fellowship for outstanding postdoctoral fellows (2009), the TR35 award by MIT review magazine for young innovators (2010), a European Research Council early career development award (2011), the Rappaport prize in biomedical research (2013), the Krill prize by the Wolf Foundation for outstanding research achievements (2013), featured among "40 under 40" innovative scientists by Cell press (2014) and recently became an EMBO member (2017).

    Abstract:

    The identity of somatic and pluripotent cells can be epigenetically reprogrammed and forced to adapt a new functional cell state by different methods and distinct combinations of exogenous factors. The aspiration to utilize such ex vivo reprogrammed pluripotent and somatic cells for therapeutic purposes necessitates understanding of the mechanisms of reprogramming and elucidating the extent of equivalence of the in vitro derived cells to their in vivo counterparts. In my presentation, I will present my group’s recent advances toward understanding these fundamental questions and further detail our ongoing efforts to generate developmentally unrestricted human naive pluripotent cells. I will conclude by highlighting new avenues for utilizing epigenetic reprogramming to naïve pluripotency for unraveling critical gene regulatory mechanisms acting during early mammalian development and highlighting prospects for new platforms for human disease and developmental modelling.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    FEB 25, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources